Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330068 · ClinicalTrials.gov registry record
Microbiome of Depression & Treatment Response to Citalopram
A clinical trial of Major Depressive Disorder, Bipolar I and Bipolar II, sponsored by Mayo Clinic.
- Completed
- Registry status
- 34
- Enrollment target
- 2
- Study locations
NCT02330068 is a study of Major Depressive Disorder, Bipolar I and Bipolar II that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02330068, a study of Major Depressive Disorder, Bipolar I and Bipolar II, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will enroll approximately 80 participants (anticipated 40 study completers with paired biomarker data) with an episode of major depression, Bipolar I or Bipolar II and 40 age- and sex-matched healthy controls.
Conditions Studied
Interventions
- DRUG citalopram
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330068
The ClinicalTrials.gov registry entry for NCT02330068 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder, Bipolar I and Bipolar II appearing as the primary indexed condition, and to 1 intervention - of which citalopram is the first listed.
NCT02330068 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02330068 about?
NCT02330068 is a clinical study titled "Microbiome of Depression & Treatment Response to Citalopram". The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will ...
What is the current status of trial NCT02330068?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2014-12. Estimated completion is 2017-12.
What conditions does trial NCT02330068 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Bipolar I and Bipolar II.
What interventions are being tested in trial NCT02330068?
The interventions under investigation include: citalopram (DRUG).
Who is sponsoring clinical trial NCT02330068?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330068 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.